Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCR-9171
- Development stage
- Preclinical
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SCR-9171 is a bispecific T-cell engager (BiTE) molecule being developed by Simcere Pharmaceutical Group for the treatment of gastrointestinal cancers. It is a biologic therapeutic designed to simultaneously target Mucin 17 (MUC17) on tumor cells and CD3 on T cells, thereby recruiting and activating the immune system to eliminate MUC17-positive cancer cells. The drug is engineered with a humanized nanobody derived from camelids and a low-affinity CD3 antibody, a design intended to optimize antitumor efficacy while minimizing the risk of cytokine release syndrome (CRS). Preclinical studies have demonstrated potent cytotoxicity and strong antitumor efficacy in mouse models, along with good tolerability in cynomolgus monkey toxicology studies.
02
Targets
CD3 (T-cell surface glycoprotein CD3)MUC17 (Mucin 17, cell surface associated)
Beyond the preview
Go deeper on SCR-9171.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCR-9171.